Objective:To investigate the regulatory effects of sodium butyrate on p53 target genes(p21waf1,bax,and gadd45)in HT-29 colorectal cancer cells and the related mechanisms.Methods:HT-29 cells were cultured in the absence or presence of sodium butyrate.The cell proliferation and cell cycle were studied by MTT and FCM,respectively.Apoptosis was assessed by observing cell morphology,percentage of sub-G_ 1 cells and AnnexinV-FITC.The effects of sodium butyrate on transcription of p21waf1,bax and gadd45 were analyzed by RT-PCR and Western blot.Results:Sodium butyrate inhibited proliferation and induced apoptosis of HT-29 cells in a time-and dose-dependent manner,and it blocked HT-29 cell at G_ 1 phase.Sodium butyrate stimulated p21waf1 and bax expression both at mRNA and protein level in HT-29 cells,but had little effect on the transcription of gadd45.Conclusion:Sodium butyrate can inhibit proliferation and induce apoptosis of HT-29 cells,which might be through up-regulating p21waf1 and bax expression both at mRNA and protein levels.

Objective To study the effect of imbalance of proliferation and apoptosis in the development of colorectal carcinoma(CRC),and the molecular mechanism of the dynamic change.Methods ORC was(induced) with dimethylhydrazine(DMH) in male mice of Kimming strain.The mice were killed in batches in the 12th,18th and 24th weeks of carcinoma induction.The distribution and extent of proliferation and(apoptosis) of the colorectal mucosa,at various intervals,were dynamically observed.Three genes,p21waf1,Bax and Gadd45 were analyzed by RT-PCR,immunohistochemistry and Western blot.Results During the course of carcinoma induction,the mucosas of the model mice showed sequential changes of atypital(hyperplasia),adenoma,and carcinoma.Compared with control group,the PCNA expression of the model group mice was significantly higher(P

Objective To evaluate efficacy and safety of Atorvastatin combined with trimetazidine Sibutramine treating angina pectoris of coronary heart disease.Methods Of computer retrieval China National Knowledge Infrastructure (CNKI),Wanfang database,VIP database and search atorvastatin statins combined with trimetazidine trimetazidine in the treatment of angina pectoris of coronary heart disease:a randomized controlled trial,according to Jadad scale to evaluate the quality of the included studies and extracted data.Meta analysis was performed using RevMan 5.3.Results In accordance with the inclusion criteria were included in the 18 study,a total of 1 848 patients.The software of RevMan 5.3 on cardiovascular events incidence,clinical curative effect,angina pectoris,blood lipid [total cholesterol (TC),triglyceride (TG),low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C)],the improvement of cardiac function [including cardiac index left ventricular end diastolic diameter (LVEDD),left ventricular end systolic diameter (LVESD)] and the adverse reactions of meta analysis showed that compared with pure atorvastatin,atorvastatin combined with trimetazidine can reduce the incidence of cardiovascular events [OR =0.19,95％ Cl (0.11,0.35),P＜0.01],reduce seizure frequency and duration of angina [WMD =-1.52,95％ CI (-1.84,-0.99),P ＜ 0.01;WMD =-1.80,95％ CI (-2.20,-1.50),P ＜0.01],improve the clinical efficiency of [OR =4.78,95％ Cl (3.54,6.47),P ＜ 0.01] display.Blood lipid and cardiac ultrasound index show that atorvastatin combined with trimetazidine can better improve the patient's LVEDD [WMD =-2.69,95％ CI (-4.39,-0.98),P ＜ 0.01] LVESD [WMD =-6.92,95 ％ CI(-11.82,-2.02),P ＜ 0.01].The decrease of serum level of TC,TG,LDL-C was better than atorvastatin monotherapy,but there were no statistically significant differences in the improvement level of serum HDL-C in the included patients (P =O.17).In the included studies,atorvastatin combined with trimetazidine can effectively reduce the incidence of adverse reactions in patients [0R=0.33,95％ CI (0.13,0.85),P=0.02].Conclusions Atorvastatin combined with trimetazidine is safer and more effective than atorvastatin alone in the treatment of coronary heart disease angina pectoris.

Objective To establish a severe sepsis/septic shock prognosis prediction model based on randomize forest law (RF model), and to evaluate the prognostic value of this model for patients with severe sepsis/septic shock. Methods 497 patients with severe sepsis/septic shock admitted to intensive care unit (ICU) of Zhejiang Hospital from September 2013 to May 2017 were enrolled. The basic data, vital signs and symptoms, biochemical indexes and blood routine indexes on the 1st, 3rd, 5th day and prognosis were collected. According to the 28-day prognosis, the patients were divided into death group and survival group, and the specific indicators about the prognosis of severe sepsis/septic shock were screened. A RF model was constructed by using the specificity indicators. The assessment effectiveness of RF model, sequential organ failure assessment (SOFA), acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ) were evaluated by receiver operating characteristic (ROC) curve analysis. Results In 497 cases of severe sepsis/septic shock, 201 cases died, 28-day mortality was 40.4%. ① According to the index difference of death group and survival group, 19 specific parameters of the RF model were selected, which included the age; 24-hour urine output, urea nitrogen (BUN), serum creatinine (SCr), platelet count (PLT) on the 1st day; heart rate (HR), mean arterial pressure (MAP), cyanosis and clammy skin on the 3rd day; temperature, HR, MAP, 24-hour urine output, PLT, fever, cyanosis, dyspneic, clammy skin, piebald on the 5th day. ② ROC curve analysis showed that the area under the ROC curve (AUC) of RF model predicting 28-day mortality was higher than that of SOFA and APACHE Ⅱ score on the 1st, 3rd, 5th day (AUC: 0.836 vs. 0.643, 0.554, 0.766 and 0.590, 0.670, 0.758). The sensitivity of RF model to predict the 28-day mortality was 86.1%, the specificity was 77.0%, the accuracy was 80.7%. Conclusion The evaluation model based on random forest can effectively predict the death risk of 28-day in patients with severe sepsis/septic shock, and its predictive efficiency is better than that of the SOFA and APACHE Ⅱ score.